Reza Shafiee-Nick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8369100/publications.pdf

Version: 2024-02-01

686830 676716 21 577 13 22 citations h-index g-index papers 22 22 22 846 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Combination of Imipramine, a sphingomyelinase inhibitor, and \hat{l}^2 -caryophyllene improve their therapeutic effects on experimental autoimmune encephalomyelitis (EAE). International Immunopharmacology, 2019, 77, 105923.	1.7	40
2	Flavonoids for preserving pancreatic beta cell survival and function: A mechanistic review. Biomedicine and Pharmacotherapy, 2019, 111, 947-957.	2.5	94
3	The protective effects of \hat{l}^2 -caryophyllene on LPS-induced primary microglia M1/M2 imbalance: A mechanistic evaluation. Life Sciences, 2019, 219, 40-73.	2.0	63
4	Promising neuroprotective effects of \hat{l}^2 -caryophyllene against LPS-induced oligodendrocyte toxicity: A mechanistic study. Biochemical Pharmacology, 2019, 159, 154-171.	2.0	56
5	Safety and efficacy of a polyherbal formulation for the management of dyslipidemia and hyperglycemia in patients with advanced-stage of type-2 diabetes. Biomedicine and Pharmacotherapy, 2017, 89, 69-75.	2.5	42
6	A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases. Biomedicine and Pharmacotherapy, 2017, 94, 541-556.	2.5	34
7	Novel cilostamide analogs, phosphodiesterase 3 inhibitors, produce positive inotropic but differential lusitropic and chronotropic effects on isolated rat atria. Iranian Journal of Basic Medical Sciences, 2017, 20, 639-647.	1.0	1
8	Pathological consequences of C-peptide deficiency in insulin-dependent diabetes mellitus. World Journal of Diabetes, 2015, 6, 145.	1.3	22
9	Pancreatic beta cell protection/regeneration with phytotherapy. Brazilian Journal of Pharmaceutical Sciences, 2015, 51, 1-16.	1.2	60
10	MC2, a new phosphodiesterase-3 inhibitor with antilipolytic and hypolipidemic effects in normal and diabetic rats. International Journal of Diabetes in Developing Countries, 2015, 35, 408-417.	0.3	2
11	Metabolic effects of newly synthesized phosphodiesterase-3 inhibitor 6-[4-(4-methylpiperidin-1-yl)-4-oxobutoxy]-4-methylquinolin-2(1H)-one on rat adipocytes. DARU, Journal of Pharmaceutical Sciences, 2015, 23, 19.	0.9	7
12	Different effects of adenylyl cyclase activators and phosphodiesterases inhibitors on cervical cancer (HeLa) and breast cancer (MCF-7) cells proliferation. Toxicology Mechanisms and Methods, 2014, 24, 307-314.	1.3	9
13	Combination of Nigella sativa with Glycyrrhiza glabra and Zingiber officinale augments their protective effects on doxorubicin-induced toxicity in h9c2 cells. Iranian Journal of Basic Medical Sciences, 2014, 17, 993-1000.	1.0	15
14	Antihyperlipidemic Effect of a Polyherbal Mixture in Streptozotocin-Induced Diabetic Rats. Journal of Lipids, 2013, 2013, 1-6.	1.9	14
15	Chronic Administration of a Combination of Six Herbs Inhibits the Progression of Hyperglycemia and Decreases Serum Lipids and Aspartate Amino Transferase Activity in Diabetic Rats. Advances in Pharmacological Sciences, 2012, 2012, 1-6.	3.7	36
16	Differential metabolic effects of novel cilostamide analogs, methyl carbostiryl derivatives, on mouse and hyperglycemic rat. Iranian Journal of Basic Medical Sciences, 2012, 15, 916-25.	1.0	3
17	Effect of Ganoderma lucidum hydroalcoholic extract on insulin release in rat-isolated pancreatic islets. Avicenna Journal of Phytomedicine, 2012, 2, 206-11.	0.1	4
18	The effect of cilostamide derivatives on lipolysis of rat retroperitoneal adipose tissue. Clinical Biochemistry, 2011, 44, S248.	0.8	2

#	Article	IF	CITATIONS
19	Inotropic and chronotropic effects of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives in isolated rat atria. Iranian Biomedical Journal, 2008, 12, 77-84.	0.4	4
20	The effect of selective phosphodiesterase inhibitors on plasma insulin concentrations and insulin secretion in vitro in the rat. European Journal of Pharmacology, 1997, 324, 227-232.	1.7	23
21	Effects of typeâ€selective phosphodiesterase inhibitors on glucoseâ€induced insulin secretion and islet phosphodiesterase activity. British Journal of Pharmacology, 1995, 115, 1486-1492.	2.7	45